(Q37882879)

24 August 2017

1 reference

title

The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? (English)

1 reference

24 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

1 reference

Jack J Chen

1

1 reference

24 August 2017

Jayne R Wilkinson

series ordinal

2

1 reference

24 August 2017

language of work or name

1 reference

31 May 2011

1 reference

The Journal of Clinical Pharmacology

24 August 2017

published in

1 reference

24 August 2017

volume

52

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

620-628

1 reference

Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

A possible L-deprenyl induced hypertensive reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

A hypertensive reaction induced by concurrent use of selegiline and dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Molecular pathophysiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Transtelephonic home blood pressure to assess the monoamine oxidase-B inhibitor rasagiline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Deprenyl administration in man: A selective monoamine oxidase B inhibitor without the ?cheese effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

MAO-B inhibitor know-how: back to the pharm

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Biogenic amines in dry fermented sausages: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Tyramine pharmacokinetics and reduced bioavailability with food

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011406279

21 January 2018

Identifiers

DOI

10.1177/0091270011406279

1 reference

24 August 2017

1 reference